Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in Localized Esophageal Squamous Cell Carcinoma
NCT03957590Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jun 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Tislelizumab + Chemoradiotherapy with Placebo + Chemoradiotherapy (2 arms). Primary endpoint: Progression-free Survival up to 67 months. Started Jun 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03957590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957590.